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ABSTRACT
Survival improvement in rectal cancer treated with neoadjuvant 
chemoradiotherapy (nCRT) is achieved only if pathological response occurs. 
Mandard tumor regression grade (TRG) proved to be a valid system to measure nCRT 
response. The ability to predict tumor response before treatment may significantly 
have impact the selection of patients for nCRT in rectal cancer. The aim is to 
identify potential predictive pretreatment factors for Mandard response and build 
a clinical predictive model design. 167 patients with locally advanced rectal cancer 
were treated with nCRT and curative surgery. Blood cell counts in peripheral blood 
were analyzed. Pretreatment biopsies expression of cyclin D1, epidermal growth 
factor receptor (EGFR), vascular endothelial growth factor (VEGF) and protein 21 
were assessed. A total of 61 single nucleotide polymorphisms were characterized 
using the Sequenom platform through multiplex amplification followed by mass-
spectometric product separation. Surgical specimens were classified according to 
Mandard TRG. The patients were divided as: “good responders” (Mandard TRG1-
2) and “poor responders” (Mandard TGR3-5). We examined predictive factors for 
Mandard response and performed statistical analysis. In univariate analysis, distance 
from anal verge, neutrophil lymphocyte ratio (NLR), cyclin D1, VEGF, EGFR, protein 
21 and rs1810871 interleukin 10 (IL10) gene polymorphism are the pretreatment 
variables with predictive value for Mandard response. In multivariable analysis, NLR, 
cyclin D1, protein 21 and rs1800871 in IL10 gene maintain predictive value, allowing 
a clinical model design. Conclusion: It seems possible to use pretreatment expression 
of blood and tissue biomarkers, and build a model of tumor response prediction to 
neoadjuvant chemoradiation in rectal cancer. 
                                                           Research Paper
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INTRODUCTION
Colorectal cancer is still one of the most common 
malignancy in Western Countries and the second in 
mortality, despite all improvements in therapeutic 
approach [1]. Treatment in locally advanced rectal cancer 
(LARC) is paradigmatic for this issue. Neoadjuvant 
chemoradiotherapy (nCRT) combined with surgery 
remains the standard treatment strategy for patients 
with LARC, but not all patient benefits with this kind 
of multimodal treatment. The responses to nCRT, range 
from none to complete, and only patients with complete 
or near complete response have improved local recurrence 
control and disease free survival [2-7]. In fact, the variety 
of tumor responses increased the need to find a useful 
predictive model, which may be helpful in the design of 
individualized treatment for rectal cancer. However, the 
accuracy of the current available imaging modalities, 
including diffusion-weighted magnetic resonance imaging 
(MRI) and positron emission tomography (PET) on 
restaging tumor after nCRT seems to be less effective 
than was expected to be [8-10]. For this reason, the search 
for biomarkers predictors of rectal cancer response to 
chemoradiation, retains all relevance and great interest 
[11, 12]. 
Several promising candidate markers have been 
reported as potential roles to predict nCRT response. In 
fact, host, tumor biology, and treatment-related factors 
may affect nCRT response and interfere with outcome 
results in LARC. Single nucleotide polymorphisms 
(SNPs), a form of study patient genetic variability, hold 
considerable promise to unveil the underlying complex 
genetics of response to CRT [13-16]. Blood cell counts in 
peripheral blood are considered to reflect environmental 
host factors in rectal tumor and may be correlated with 
survival and even tumor response [17-19]. CEA level, 
tumor size, distance from anal verge, differentiation 
grade, as well molecular features, are pretreatment tumor 
aspects that can be related with tumor response [20-
27]. Between these aspects, molecular features assume 
particular relevance reflecting the tumor biology. In this 
area, multiple attempts by individual molecular markers 
in tissue microarray studies have emerged with the goal 
of identifying predictors of a response to chemoradiation 
in patients with rectal cancer [28, 29]. The expression 
of several biomarkers in pretreatment biopsies, such 
cyclin D1, p21, EGFR and VEGF have been associated 
with tumor response to nCRT. On the other hand, 
chemoradiotherapy scheme selection and interval of time 
between nCRT and surgery are treatment-related factors 
that can constrain nCRT response magnitude [30-33]. 
Our objective was to assess whether neutrophil 
lymphocyte ratio (NLR) in pretreatment blood sample, 
pretreatment biopsies expression of cyclin D1, EGFR, 
VEGF and p21, and 61 tagSNPs (genomic DNA was 
extracted from peripheral blood leukocytes or tumor 
tissue) could be used to predict pathologic response in the 
setting of rectal cancer treated in a single tertiary center 
with nCRT followed by surgery. Mandard TRG were 
measured and used to define tumor response. The patients 
were divided as: “good responders” (Mandard TRG1-2) 
and “poor responders” (Mandard TRG3- 5). According to 
the results from our previous data, good responders have 
better prognosis than poor responders [34, 35]
RESULTS
Description of study population and clinical 
parameters
This cohort study gathered 186 consecutive patients 
with LARC treated with nCRT follow by curative surgery 
with total mesorectal excision at one single University 
Hospital. After the exclusion of 11 patients with positive 
radial margin (R1 surgery), for 4 patients with yp stage IV, 
and four deaths within 60 postoperative days, 167 patients 
were included in the present analysis, with a median age 
of 64.6 years (range = 29-83 years). The male to female 
ratio was 1.69:1. The clinical parameters are summarized 
in Table 1. Description of Study Population
Polymorphism study
Three SNPs were excluded from the analysis due to 
genotyping failure, leaving a total of 58 to be included in 
the survival analysis: 29 in ABCC4, 15 in SLCO2A1, seven 
in HPGD, and one each in COX2, EGFR, CCND1, IL10, 
TNFA, IGF1 and NAT2 genes. Description, frequencies 
and predictive response value of selected SNPs in the 167 
patients are given in Supplementary Table S1b.
Biopsy characteristics
The biopsy characteristics including 
immunohistochemical expression of cyclin D1, p21, 
EGFR and VEGF are shown in Table 2.
Surgery
Sphincter-saving rectal resection with anastomosis 
(with or without protective ileostomy) was performed 
on 107 patients (64.1%). Abdominoperineal resection 
was performed on 53 patients, and seven patients were 
subjected to proctectomy with definitive stoma. The 
perioperative morbidity of the series was 25.1%, with 16 
abdominal or pelvic abscesses, three anastomostic leaks, 
that included six reoperations (due to three leakages and 
three abdominal abscesses), and three re-admissions (due 
to pelvic abscess).
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Pathology of resected specimens
Stage distribution is shown in Table 3.
The average number of dissected lymph nodes in the 
surgical specimens was 8 (range = 0-22). Circumferential 
resection margin > 1 mm was confirmed in all 167 
patients.
Response to neoadjuvant therapy is characterized in 
Table 3. Tumor downstaging was observed in 67 patients 
(40.1%). 
Reduction in T-stage by one level was observed 
in 29 patients (17.4%) and by two or more levels in 38 
patients (22.8%). Observations indicating pathological 
downstaging are given in Table 3. Ninety five (56.8%) 
patients presented one or lower pathological stage than 
their initial clinical tumor stage. ypCR or Mandard TRG1 
was confirmed in 31 patients (18.5%). The use of Mandard 
system allowed us to define two groups as previously 
mentioned: good responders (Mandard TRG1-2) and 
poor responders (Mandard TRG3- 5). Using the Mandard 
system, a good response to nCRT was found in 86 patients 
(51.4%) and a poor response in 81 (48.5%).
Clinical outcome
Table 4 shows long-term clinical outcome, relapse 
of disease and survival. With a median follow-up of 64 
months (range = 6-148 months), 5-year DFS was 73.3% 
and pelvic control was 95.8%. Seven patients (4.2%) 
developed pelvic recurrence (five isolated and two with 
synchronous metastatic disease) and 22 (13.2%) distant 
metastases alone. Two of the seven pelvic recurrences 
occurred later in the outcome - after 18 months of follow-
up (at 28 and 45 months, respectively). Twelve out of 
167 patients had more than 24 but less than 42 months 
of follow-up. Local recurrence increased slightly to 4.5% 
(7/155) when considering only patients with more than 42 
months of follow-up.
Using results from a fitted Cox model, the estimated 
hazard ratio is 5.16: this means that the poor responders 
have a probability of death five times higher than good 
responders ( Cox model survival HR = 5,16 C.I. 95% 
2,638-10,114).
Figure 1: Immunohistochemistry study of biopsies (Cyclin D1 and p21) showing representative examples of weak and 
strong staining (x200 and x100).
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Predictive factors of Mandard response in 
pretreatment variables
A logistic regression analysis was used to assess 
the independent significance of pretreatment variables as 
predictive factors of Mandard poor response (TRG3-5). 
In this study, all variables were analyzed before 
neoadjuvant treatment, once our aim is to predict tumor 
response before beginning CRT. 
In polymorphisms study, only one genetic 
polymorphism (rs1800781) in IL10 gene has a predictive 
response value. The others pretreatment variables with 
significant predictive value are anal tumor distance, cyclin 
D1, p21, EGFR and VEGF in biopsies and neutrophil 
lymphocyte ratio in blood samples. The remaining 
variables of Tables 1, 2 have no significant predictive 
value.
Table 5 shows these seven variables with predictive 
value for Mandard response in univariate analysis.
Table 1: Clinical parameters of patients included in this study.
Pre-CRT CEA: pre-chemoradiotherapy carcinoembryonic antigen; NLR: neutrophil lymphocyte ratio. cT stage: clinical T 
stage of TNM staging system; AAR: anterior abdominal resection; SSO: sphincter-saving operation; APR: abdominoperineal 
resection.
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The seven variables were entered as covariates into 
the logistic regression ( method: forward likelihood ratio). 
This selection was based upon their statistical significance 
in univariate analysis and their potential clinical 
interaction. In the multivariate analysis, after adjustment 
for the effects of the other variables, NLR, Cyclin D1, p21 
and rs1800871 in IL10 gene were more likely to present a 
poor response (Table 6). 
Considering the equation of the logistic probability 
model obtained from the Table 6 : e = eg(ˣ) / 1 + eg(ˣ) , 
we can calculate the probability of a patient with a poor 
Mandard response. 
For example, if the patient has the best scores: 
g(x) = -1.487- 0.441 rs1800871 GG = -1.928 ;
Mandard poor response = 0.145/1+0.145 = 0.126
The probability of the patient with a Mandard poor 
response will be 0.126
If the patient has the worst scores :
g(x) = -1.487+1.106 NLR ≥3 + 1.436 Cyclin D1 + 
1.755 p21 + 1.425 rs1800871 AA = 4.235 ; 
Probability of Mandard poor response = 69.06/ 
70.06 = 0.985
The probability of Mandard poor response will be 
0.985
If we consider the first patient in our database:
g(x) = -1.487+ 1.106 (NLR≥3) + 1.755 (p21 > 3) - 
Table 2: Biopsy characteristics.
EGFR: epidermal grow factor receptor; VEGF: vascular endothelial growth factor; 
p21: p21 protein or cyclin-dependent kinase inhibitor or CDK-interacting protein 1
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Table 3: Characteristics of resected specimens 
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0.441 (rs1800871GG) = 0.933 ; 
Probability of poor response = 2.542 / 3.542 = 0.717
So, applying for the first patient that has a NLR > 3 
and a p21 > 3 and a RS1800871GG, we would predict that 
it will likely have a poor Mandard response as the estimate 
probability of 0.72 is greater than 0.5. 
DISCUSSION
The true benefit of neoadjuvant chemoradioteraphy 
in LARC is achieved only when tumor response is 
complete or near complete [4, 5]. In those cases, tumor 
downsizing and downstaging, usually allows sphincter 
saving procedure and better local control disease and 
survival [36-38]. In selective cases, with complete 
response, surgery may be avoided and “watch and wait” 
policy is defensible [39, 40]. However, when tumor 
response is poor, during the time between the completion 
of CRT and surgery, we may have tumor progression. So, 
the prediction of tumor response before beginning CRT 
is a relevant issue that can affect the therapeutic strategy.
In this regard, the first difficulty is the definition and 
quantification of tumor response. In our previous research, 
Mandard tumor regression grade showed good accuracy 
when patients were divided as: “good responders” 
(Mandard TRG1-2) and “poor responders” (Mandard 
TRG3- 5). According to our results, good responders 
have better prognosis than poor responders. [34, 35, 41] 
This way to assess tumor response , proved to be easy, 
reproducible and related with survival. Others studies 
confirmed our findings [2-4, 42, 43] and for this reason 
we apply this concept to define tumor response. 
The second hindrance was to find pretreatment 
variables with predictive value to Mandard response. 
Like others series, most of current pretreatment CRT 
Table 4: Long-term clinical outcome, relapse of disease and overall survival (DFS).
*Significantly different at p < 0.001 (log-rank test); se: standard error.
ypT Stage: Pathological postneoadjuvant therapy T stage of TMN staging system; ypN stage: pathological postneoadjuvant 
therapy N stage of of TMN staging system; CRM: circumferential radial margin; Mandard TRG: Mandard tumor regression 
grades; IHC study: immunohistochemistry; EGFR: epidermal growth factor receptor; VEGF: vascular endothelial growth 
factor; p21: p21 protein.
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Table 5: Predictive value of pretreatment variables to Mandard response (Univariate analysis of logistic regression: 
dependent variable Mandard good response – 0; Mandard poor response – 1) C.I. 95%
NL ratio: neutrophil lymphocyte ratio; p21: p21 protein; EGFR: epidermal growth factor receptor; VEGF: vascular endothelial 
growth factor; rs 1800871 single nucleotide polymorphism of interleukin 10 (IL 10) gene
Table 6: Multivariate stepwise forward analysis LR; dependent variable – Mandard response (good response = 0; poor 
response = 1)
NL ratio: neutrophil lymphocyte ratio; p21: p21 protein; rs 1800871: single nucleotide polymorphism of interleukin 10 (IL 
10) gene
Estimated logistic probability of Mandard response = eg(ˣ) / 1 + eg(ˣ)
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clinical parameters showed no statistical significance to 
response prediction [3, 22, 35, 44]. In our study, from 
all, only tumor distance from anal verge has predictive 
value of Mandard response in univariate analysis who 
disappeared in multivariate analysis. This aspect led 
us to investigate host and tumor and related factors that 
may affect nCRT response. Three different areas were 
selected: inflammatory systemic markers, biomarkers IHC 
expression in pretreatment biopsies and polymorphisms. 
Systemic inflammatory response interfere 
with survival in patients operated with several types 
of cancer, including colorectal cancer and can also 
affect tumor chemoradiotherapy response [18, 45]. An 
elevated lymphocyte count is associated with enhanced 
downstaging following neoadjuvant CRT for locally 
advanced rectal cancer [23]. However, the value of 
this ratio is variable in different cancers. Studies of the 
relationship between NLR and both survival and response 
to chemoradiation have been limited with respect to locally 
advanced rectal cancer [17, 19]. In our study, pretreatment 
NLR value with the cutoff of 3, based in ROC analysis, 
has a predictive value to Mandard response. The main 
advantage is the ease to measure routinely because of its 
low cost. 
The broad and unpredictable response to tumor 
of patients with rectal cancer treated with neoadjuvant 
Table 7: IHC score calculation
Figure 2: Immunohistochemistry study of biopsies (EGFR and VEGF) showing representative examples of weak and 
strong staining (x200 and x100).
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chemoradiation shows that our understanding of the 
molecular events leading to radioresistance in patients 
affected with this malignancy remains sparse. The 
expression of several biomarkers in pretreatment biopsies 
has been associated with tumor response to nCRT. 
Immunohistochemistry was the most commonly used 
method for detecting protein markers in tumor tissue. 
Epidermal growth factor receptor (EGFR), vascular 
endothelial growth factor (VEGF), COX-2, thymidylate 
synthase, the p53 tumor suppressor and key mediators 
of cell-cycle arrest (p21, p27) and apoptosis (Bcl-2) 
are among the immunohistochemical protein markers 
currently of interest as potential predictors of pathologic 
response, prognosis and recurrence-free survival in 
rectal cancer following neoadjuvant therapy [46-53]. We 
selected four - cyclin D1 and p 21 that interfere in cell 
cycle and are related with cell proliferation, EGFR and 
VEGF related with angiogenesis and tumor progression. 
Cyclin D1 regulate progression from the G1 phase 
of the cell cycle to the S phase. As key regulators of 
the G1 progression step within the cell cycle, cyclin D1 
may play a pivotal role in the process of carcinogenesis 
and cancer progression [6]. The ability of cyclin D1 to 
drive the cell cycle forward can be blocked by cyclin D1-
dependent kinase (CDK) inhibitors, such as p27 and p21, 
and can explain why co-expression of cyclin D1 and p21 
contributed to the role of cyclin D1 for tumor proliferation. 
Immunostaining for cyclin D1 was predominantly nuclear 
but cytoplasmic staining was detected in some cases. 
However, unless a nuclear staining was also detected, 
cases with cytoplasmic staining were considered negative. 
Cyclin D1 overexpressed has been reported to occur in 
40-70% of colorectal tumors [54, 55]. Recently, Li et 
al. published a meta-analysis of observational studies 
that indicate Cyclin D1 overexpression, based on the 
nuclear staining is related with poor clinical outcome in 
colorectal cancer patients [56]. The cyclin D1 predictive 
value of tumor response value in pretreatment tumor 
rectal biopsies is little studied. Moral et al, between 
immunohistochemistry markers studies (p53, cyclin D1, 
Ki67, and bcl-2 protein), only found a trend towards 
significance for cyclin D1 [57]. 
Figure 3: Mandard Tumor Regression Grade System (representative examples; hematoxylin and eosin (H&E) staining; 
x200 and x100).
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p21 (Waf1/Cip1) is known as one of the cell cycle 
inhibitors which plays a role through the p53 dependent or 
independent pathway. p21 expression in tumor cells serves 
the cell proliferation ability and protects against DNA 
damage by cell cycle inhibition. p21 is a tumor suppressor 
gene that, once activated in response to DNA damage, 
causes the cell to arrest in G1 through the interruption of 
cyclin-dependent kinases [58]. In malignant cells, wild-
type p21 suppresses apoptosis in the presence of DNA 
damage caused by chemotherapeutic agents or radiation 
[59, 60]. This may explain why high p21 expression at 
the pretreatment biopsy may be associated with tumor 
regression and poor prognosis in patients treated with 
5-FU based CRT [51], but few publications have studied 
this aspect.
The present study showed that high cyclin D1 and 
high p21 expression level in the pre-CRT tumor simple 
were associated with poor pathologic regression (Mandard 
poor response). This is a concordant result considering the 
mechanism of action of these biomarkers. 
Nevertheless, some studies show agreeing results 
with ours [51, 61, 62] and others don’t, probably due to 
the selected technique. Immunohistochemistry is highly 
dependent on the antibody clone that is used, staining 
protocols, selection of scoring methods and nuclear/
cytoplasmic staining account .
EGFR is a 170-kDa transmembrane tyrosine kinase 
receptor that belongs to a family of receptors known as 
the ErbB family. EGFR is known to activate a cascade of 
multiple signaling pathways that facilitate tumor growth 
process. EGFR expression was reported to be correlated 
with more aggressive disease, increased risk of metastases, 
advanced tumor stage. Usually, IHC EGFR overexpression 
in tumor tissue implies worst outcome in colorectal cancer 
[63]. Also, Azria et al. found worst prognosis in patients 
with higher EGFR expression in pretreatment tumor rectal 
biopsies tissue [64] and Kim et al. found a predictive value 
of tumor downstaging absence when a high level of EGFR 
expression is present [46].
VEGF high expression is associated to tumor 
aggressiveness, poor survival, local failure and the 
presence of metastatic disease [65] . VEGF, is a mediator 
of tumor angiogenesis. New blood vessels induces 
increased permeability, causing less efficient delivery 
of chemotherapeutic agents and a decreased response 
to radiotherapy [66]. For this reason, VEGF assessed 
immunohistochemically from pretreatment tumor biopsies, 
may be a useful marker in the prediction of tumor 
response to preoperative CRT. High VEGF expression 
in pretreatment biopsies are correlated with poor tumor 
response in locally advanced rectal cancer treated with 
neoadjuvant chemoradiation [67]
In our study we found high expression on 
pretreatment biopsies of EGRF and of VEGF related with 
worse tumor response, but without predictive statistic 
value of tumor response (in univariate and multivariate 
analysis for VEGF and in multivariate analysis for EGRF). 
This result, may be related with intense staining for VEGF 
and EGFR pretreatment biopsies for the most of the slides. 
Once again, published conflicting results can 
be found [68, 69]. Some of them are retrospective 
in nature, with a relatively small patient number and 
different methodologies, making it difficult to draw firm 
conclusions or carry out cross-study comparisons. 
Despite this, in our study, cyclin D1 and p21 
immunohistochemical expression in pretreatment biopsies 
have prediction value and are two of the four variables 
that contribute for the statistical model capable to predict 
Mandard tumor response.
The molecular markers in tissue microarray 
studies remains attractive: can be performed in small 
samples such as biopsies , the amount of commercially 
antibodies spent are small, making the procedure feasible 
and inexpensive. However, immunohistochemistry has 
limitations: related to reproducibility and the ability to 
provide quantitative information and depending on the 
sample representativeness, immunotyping selected and 
scale used. We believe that difficulties are diminished with 
the procedure standardization and systematic application 
on a large scale. 
Polymorphisms were another field of interest that 
can help to identify Mandard good and poor responders. 
Polymorphisms of genes related mainly with inflammation 
were selected, since chronic intestinal inflammation is a 
well-known risk factor for colorectal cancer [70]. Cancer 
arises in chronically inflamed tissue. IL-10 and COX-
2 are important mediators of intestinal inflammation. 
IL-10 is a key anti-inflammatory cytokine orchestrating 
the innate and adaptive immune response. Elevated 
cyclooxygenase-2 (COX-2) expression was found in 
most colorectal cancer tissue and is associated with 
worse survival. COX-2 plays a role in tumor progression, 
stimulation of angiogenesis, promotion of metastasis, 
and decrease of the antitumor immune response. For this 
reason we selected SNPs of COX-2/HPGD/SLCO2A1/
ABCC4 Prostaglandin E2 pathway genes and IL10 gene 
among others. In our data, out of the 61 SNPs assessed, 
only the rs1800871 (C-592A) have a predictive value of 
Mandard response. The rs1800871 is a polymorphism of 
IL10 gene and has been associated with colorectal cancer 
risk [71-73]. No previous study described a relationship 
between this polymorphism and tumor response to 
chemoradiotherapy. The main handicap of this technique 
is the no availability in most hospitals, being an obstacle 
to its application in clinical practice. 
Nevertheless, with these four pretreatment variables 
(NLR, Cyclin D1, p-21 and rs1800871) it is possible to 
build a predictive clinical model of tumor response. It 
allows subset the patients according to the probability 
of response and make possible to modify the therapeutic 
plan for the putative “poor responders”. For example, 
if the patients have the best score on four variables, 
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the probability in the model to have a “poor response” 
(Mandard TRG3-5) will be 12.6% (Table 6). In this group 
the patients nCRT is a good choice with the possibility 
of a good survival. On the other hand, in patients with 
the worst score the probability to have a “poor response” 
(Mandard TRG 3-5) will be 98.5% (Table 6). In this case, 
an alternative therapeutic may be preferable. For instance, 
a short course of neoadjuvant radiation instead nCRT may 
be a better option, with less side effects, less costs and the 
possibility to begin adjuvant chemotherapy sooner. 
So, this predictive clinical model, in conceptual 
terms, is an interesting tool and can be used to decide 
between nCRT versus short course radiation, since both 
options do not differ in terms of survival. The advantage of 
our study is to had been performed in a single institution 
under the same criteria by a main skilled pathologist. The 
limitations which may have, are related to small number 
of the patients recruited, and the variability inter-observer 
that can exist in assessing of pretreatment biopsies IHC 
stains. Thus, the results of our study must be confirmed in 
regard of accuracy and reproducibility by other large and 
prospective studies with standard method of staining and 
reporting is adopted. 
CONCLUSION
It seems possible to use pretreatment expression of 
blood and tissue biomarkers and build a clinical model of 
tumor response prediction to neoadjuvant chemoradiation 
in rectal cancer. This clinical model may help in the 
therapeutic choice for locally advanced rectal cancer 
but, first it needs to be validated , and larger prospective 
clinical trials must be done, before considerer able to 
guide preoperative therapy choices in LARC.
MATERIALS AND METHODS
Ethics approval
This project was approved by the Research Ethics 
Health Committee (references188-CES) and Department 
of Education, Development and Research (reference 133-
DEFI) of the Hospital Center of Porto. Informed consent 
from patients whose tissue was archived was not required 
as per Ethics Board guidelines. Patient informed consent 
for the use of blood and tissue for genetic polymorphism 
was obtained.
Patient population
A consecutive series of patients with, biopsy-
proven LARC, who underwent nCRT followed by elective 
radical surgery with total mesorectal excision (TME) with 
curative intent between January  2003 and  December 
2013 were recruited after reviewing the clinical database 
at the Digestive Surgery Service, University Hospital 
Center of Porto, which is a tertiary referral center for a 
population of 728,663 inhabitants. All patients with rectal 
cancer (T2N+M0 or cT3/4 N0/+M0) located at less than 
12 cm of distance from the anal verge who received nCRT 
and were operated within 8 weeks after radiotherapy 
ended were included, if none of the following exclusion 
criteria were found: other diagnosed neoplasia, short 
course radiotherapy, post neoadjuvant stage IV, R1/R2 
surgery, and postoperative death within 60 days.
Diagnosis and staging criteria
Staging included rigid proctoscopy, total 
colonoscopy, chest, abdominal and pelvic computed 
tomographic scan, endorectal ultrasound, pelvic 
magnetic resonance image (since 2008), and serum 
carcinoembryonic antigen (CEA) level.
nCRT protocol
This protocol included total irradiation of 50.4 Gy in 
28 fractions and 5-fluorouracil (5-FU) by infusion pump 
(225 mg/m2/day, 7 days per week, from the first until 
the last day of radiotherapy) or capecitabine (2500 mg/
m2/day, divided in two doses, from de first until the last 
day of radiotherapy). All patients receiving nCRT were 
operated on within 8 weeks after radiotherapy ended. All 
patients received pelvic radiation therapy with concurrent 
chemotherapy. The option between 5-fluorouacil and 
capecitabin was made based on patient comorbilities and 
drug tolerance.
Treatments were given with a linear accelerator with 
a minimum energy of 10MeV. The total dose of radiation 
therapy was 50.4 Gy. Patients underwent CT simulation 
with oral contrast to visualize the small bowel. All 
patients underwent three-dimensional conformal radiation 
treatment planning. The intent of treatment was to include 
the tumor bed (gross tumor volume) with a margin, the 
internal iliac nodes, and the presacral nodes (the external 
iliac nodes were also included if a structure was invaded 
that drained to the external iliacs) to a total dose of 45 Gy. 
This was delivered at 1.8 Gy per day, 5 days per week, 
or 25 fractions over 5 weeks. A minimum tumor boost of 
540 cGy, given at 1.8 cGy per fraction, was required for 
all patients and was given to the gross tumor volume with 
a 1-cm margin. Normal tissue sparing techniques were 
employed so that no portion of the small bowel received 
more than 4500 cGy and less than 10% of the bladder 
receive greater than 5000 cGy.
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Surgical procedures
Radical surgery consisted mainly of sphincter-
saving rectal resection or abdominoperineal resection both 
with total mesorectal excision. Regarding the selection of 
the operative procedure, we considered the distance of the 
lesion from the anus, the comorbidities of the patient, and 
the condition of the anal sphincter.
Adjuvant chemotherapy protocol
Post surgery, patients were administered adjuvant 
chemotherapy protocol for 6 months performed preferably 
with 5-FU or a combination of 5-FU and oxaliplatin (one 
of the followed regimens: mFolFOX6 - 200 mg/m2 
folinic acid (FA) day 1, 400 mg/m2 5-FU bolus day 1, 
continued infusion for 46 hours of 2400 mg/m2 5-FU and 
85 mg/m2 oxaliplatin, 14/14 day cycle; CapeOx: 1000 
mg/m2 capecitabine twice a day, days 1-14, 130 mg/m2 
oxaliplatin day 1, 21/21 day cycle; 5-FU/FA: 200 mg/
m2 FA day 1, 400 mg/m2 5-FU bolus day 1, continued 
infusion for 46 hours of 2400 mg/m2 5-FU, 14/14 day 
cycle).
mFolFOX6 or capeOX were the preferred regimens. 
When the administration of oxaliplatin is not possible 
due to side effects of the drug or the comorbidities of the 
patient, one of followed regimens was used: 5-fluorouracil/
folinic acid (5-FU/FA) 200mg/m2 folinic acid (1-hour 
infusion prior to 5-FU) and 400mg/m2 5-FU per day 
intravenously once daily x 5 every 5 weeks or 1000 mg/
m2 capecitabine twice a day x 5 every 5 weeks.
Systemic inflammatory markers
Blood samples from all patients were collected 
within 7 days before starting nCRT protocol. White blood 
cell, neutrophil, lymphocyte, and platelet counts were 
recorded. The neutrophil to lymphocyte ratio (NLR) 
was calculated as the neutrophil count divided by the 
lymphocyte count using preoperative blood test results. 
An NLR ≥3 was considered elevated (based on receiver 
operating characteristic curve analysis).
Pretreatment biopsy samples - hematoxylin and 
eosin (H&E) staining and immunohistochemistry 
(IHC)
Diagnostic pretreatment paraffin-embedded biopsies 
were available and reviewed by a pathologist blinded 
to clinical data. Tumor biopsy sample classification, 
including grade, were obtained for the worst tumor areas 
whenever available material contained several areas 
with neoplasia. The mitotic index was the number of 
mitoses for 10 high-powered fields and the cut-off was 
chosen taking into account the best ratio of sensitivity to 
specificity. In the absence of neoplasia in 10 high-power 
fields, the number of mitoses was counted in the number 
of observed fields, estimating the value for 10 fields. 
IHC for cyclin D1, p21, epidermal growth factor 
receptor (EGFR) and vascular endothelial growth factor 
(VEGF) were performed in tissue arrays constructed 
from core tissue specimens (preoperative endoscopic 
biopsy) taken before treatment. Representative core 
tissue specimens (2 mm in diameter) were taken from 
individual paraffin blocks and rearranged in new tissue 
array blocks using a trephine apparatus (Superbiochips 
Laboratories, Seoul, Korea). Array slides were labeled 
by IHC with four commercially available antibodies 
to: cyclin D1 (1:1000; BD Biosciences, MA, USA), 
p21 (1:300; Spring Bioscience, CA, USA), EGFR 
(1:200; Abcam, MA, USA), and VEGF (1:30 dilution; 
BD Biosciences). Antigen retrieval was performed 
by immersing the slides in citrate buffer (pH 6.0) and 
microwaving them for 10 minutes. Nonreactive sites were 
blocked using 1% horse serum in Tris-buffered saline (pH 
6.0) for 3 minutes. Primary antibodies were applied, and 
antibody binding was detected using the avidin-biotin 
peroxidase complex (Universal Elite ABC kit PK-6200; 
Vectastain, Burlingame, CA, USA) and diaminobenzidine 
tetrahydrochloride solution (Kit HK 153-5 K; Biogenex, 
San Ramon, CA, USA). We performed the IHC procedure 
without primary antibody for negative controls. Normal 
colorectal epithelial cells were used as internal negative 
controls. 
The location of staining, nuclear, membranous, or 
cytoplasmic, was recorded. The percentage of positively 
stained cells were assigned to one of four categories for 
protein expression: 0%, 0; 1-25%, 1; 26-50%, 2; > 50%, 
3. The staining intensity was scored as follows: none or 
weak, 0; moderate, 1; intense, 2. If the staining intensity 
was heterogeneous in a section, it was scored based on 
that which was predominantly observed. The two scores 
(if different from zero) were then multiplied to produce 
a weighted score for each tumor specimen (Table 7). The 
final score was grouped as follow 0-3, weak; ≥4, strong 
(Figure 1 and 2).
The samples were scored by 2 independent analysts 
blinded to the patients’ clinical information. Expression 
of each protein was quantified using a visual grading 
system, based on the extent of the tumor staining. The 
mean value for the expression of each biomarker was then 
calculated. Tumor staining at a level higher than the mean 
was considered to indicate high expression, while staining 
at a level lower than the mean was considered to indicate 
low expression. The consistency of the expression scores 
between the 2 independent observers was greater than 
90%. In cases of disagreement, the expression level was 
determined by consensus.
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Sample collection and biological processing for 
DNA analysis
DNA was extracted preferably from blood or 
alternatively from tumor tissue. Blood samples were 
collected with a standard venipuncture technique 
using EDTA-containing tubes before the beginning of 
neoadjuvant therapeutic. Genomic DNA was extracted 
from peripheral blood leukocytes, using the QIAamp 
DNA Blood Mini Kit (Qiagen, Madrid, Spain) following 
the manufacturer’s instructions.
For patients unable to provide a blood sample, 
the DNA was extracted from formalin-fixed paraffin-
embedded blocks from the Pathology Department at our 
Hospital. Two to four 10-mm thick section were used in 
each extraction depending on the size of tissue area (1.5-
3 cm2). Briefly, the tumor tissue specimens from each 
glass slide were scraped, using a clean razor blade, into 
a 1.5-ml microcentrifuge tube followed by centrifugation 
at 14000-16000 × g for 3 minutes. The tissue pellets were 
then rehydrated with 1 ml of absolute ethanol, followed 
by centrifugation at 14000-16000 × g for 3 minutes and 
the supernatant was discarded. This step was repeated 
twice. The tube was left open for 15 minutes to allow 
any remaining ethanol to evaporate. Further steps of 
DNA isolation were performed using the GRS Genomic 
DNA Kit. Tissue, in accordance with the manufacturer’s 
protocol (GRiSP, Porto, Portugal).
DNA was quantified using a NanoDrop 1000 
Spectrophotometer (Thermo Fisher Scientific, Wilmington, 
DE, USA) and stored at -20˚C until genotype examination. 
The DNA quality was determined by measuring the optical 
density (OD) 260/280 ratio.
Polymorphism selection
The strategy for polymorphism selection has 
been described elsewhere [74]. Briefly, using a tagSNP 
approach, the genetic variants were retrieved from a set 
of common SNPs in the Caucasian population of HapMap 
project (CEU) (https://ncbi.nlm.nih.gov). The Genome 
Variation Server (version 7.00) was used to recover 
tagSNPs capturing variations (i) with a minor allelic 
frequency of 15% or more; (ii) within the coding region of 
the genes plus 2 kb upstream and downstream, (iii) with a 
r2 greater than 0.8, and (iv) which successfully converted 
to the Sequenom platform (Sequenom, San Diego, CA, 
USA). A total of 55 tagSNPs were analyzed in COX2, 
HPGD, SLCO2A1 and ABCC4 PGE2 pathway-related 
genes.
Furthermore, rs2946834 insulin-like growth factor 
1 (IGF1), rs1801280 N-acetyltransferase 2 (NAT2), 
rs1800629 tumor necrosis factor-alpha (TNFA), rs9344 
cyclin D1 (CCND1), rs2227983 EGFR, and rs1800871 
interleukin 10 (IL10) polymorphisms, previously found 
to be associated with colorectal tumor development, were 
also included.
Genotype characterization
TagSNP genotyping was performed using 
MassARRAY iPLEX Gold technology (Sequenom) 
based on multiplexed amplification followed by mass-
spectrometric product separation. This technique was 
carried-out by the Genomic Unit, Genotyping Service, 
Gulbenkien Science Institute.
Resected specimen samples - H&E staining and 
IHC
Immunohistochemical staining for cyclin D1, 
p21, EGFR and VEGF was performed in tissue arrays 
constructed from core tissue specimens taken from the 
resected specimen using the methodology applied in 
pretreatment tumor biopsies.
Standard pathological tumor staging of the resected 
specimen was performed in accordance with the guidelines 
of the American Joint Committee on Cancer (http://www.
cancerstaging.net). The circumferential resection margin 
was scored as positive when cancer cells were within 
1 mm of the margin. Evidence of pathologic complete 
response after neoadjuvant treatment (ypCR) was defined 
as an absence of viable adenocarcinoma in the surgical 
specimen or the presence of lakes of mucus without tumor 
cells. The histology of all surgical specimens was reviewed 
and confirmed by a pathologist blinded to clinical data 
and they were classified based on the Mandard tumor 
regression grading system [75].
The number of tumor samples taken from the 
resected specimens was variable, with a mean of six 
paraffin blocks per case. The methodology used was the 
following: five samples were taken from the area with 
macroscopic lesion (assuming it existed), i.e. in the same 
manner as dealing with a specimen from a patient who 
had not received neoadjuvant therapy. These included the 
closest macroscopic approach of the macroscopic lesion 
to the peritoneal surface or the mesorectal excision plane, 
as appropriate. If no viable tumor was identified within 
the initial five blocks, the whole of the remainder of any 
macroscopic lesion in additional blocks was included. If 
no viable tumor was identified within these extra blocks, 
another three further levels from all of these blocks were 
taken. If no viable tumor was identified in these sections, 
then complete histological tumor regression was assumed.
All obtained slides were seen and reviewed 
by the same experienced pathologist blinded to 
clinicopathological data. Items observed and registered in 
the biopsies were subsequently analyzed in the resected 
specimen and the same criteria adopted.
Patients were then divided in two groups according 
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to the Mandard TRG system, good responders were 
defined as Mandard TRG1 orTRG2; poor responders were 
defined as Mandard TRG3, TRG4 or TRG5 (Figure 3). 
Both groups (good versus poor responders) were used to 
evaluate outcomes.
Survival and disease recurrence definitions
Disease recurrence was evaluated according to 
location: locoregional (LR), systemic (DR), or mixed. 
All surviving patients were followed-up and their current 
status was confirmed. None of the patients were lost from 
follow-up. Disease-free survival (DFS) was calculated 
from the first date of neoadjuvant treatment to the date of 
progression (local or distant), and overall survival (OS) 
was calculated from the first date of treatment to the date 
of death or last follow-up.
Statistical analysis
The survival function was estimated using the 
Kaplan-Meier method. The difference in survival rates 
between groups was tested for significance using the log-
rank test. The significance of differences in proportions 
was calculated with Chi-square test and the differences 
in means with Student’s t test. A logistic regression 
analysis was used to assess the independent significance 
of factors predictive of response, defined as “good” or 
“poor” responders (TRG1- 2/TRG3-5): age; gender; 
clinical stage; anal-tumor distance; pre-treatment blood 
samples of CEA and NLR assay; samples biopsies pre-
treatment immunohistochemical expression of cyclin D1, 
EGFR, VEGF and p21; and 61 tagSNPs were studied.
The statistical analysis was made with SPSS statistical 
software (version 21.0 for Windows; SPSS Inc., Chicago, 
IL). All statistical tests were conducted at a two-sided 
level of significance of 0.05.
Supporting Information
Supplementary Table S1b Description, frequencies 
and predictive response value of selected SNPs in the 167 
patients. 
Availability of data and materials
This is an observational cohort research study with 
a prospective registration. The data and materials are 
available in Surgery Department of Hospitalar Center of 
Porto, Portugal.
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